Drug Profile


Alternative Names: HOE-239

Latest Information Update: 16 Oct 2015

Price : $50

At a glance

  • Originator Hoechst Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class Antiparasitics; Nitroimidazoles
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Trypanosomiasis
  • Phase II Chagas disease; Visceral leishmaniasis

Most Recent Events

  • 01 Sep 2015 The DNDi terminates phase II trial in Visceral leishmaniasis in Sudan (NCT01980199)
  • 01 Jul 2015 Phase-II clinical trials in Chagas' disease in Bolivia (PO)
  • 16 Jun 2015 Phase-II/III development for Trypanosomiasis (patients aged ≥15 years) is ongoing in Democratic Republic of the Congo and Central African Republic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top